Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-25 @ 3:45 AM
Ignite Modification Date:
2025-12-26 @ 2:32 AM
NCT ID:
NCT00778102
Group ID:
EG000
Title:
Bevacizumab + mFOLFOX-6
Description:
Participants received a chemotherapy regimen of bevacizumab plus mFOLFOX-6. Each drug was administered on Day 1 of each 2-week cycle. Dosing was as follows: bevacizumab 5 mg/kg via IV infusion; oxaliplatin 85 mg/m\^2 via IV infusion; leucovorin 400 mg/m\^2 via IV infusion; 5-FU 400 mg/m\^2 via IV bolus; and 5-FU 2400 mg/m\^2 via continuous 46-hour IV infusion. Following completion of 12 cycles, participants could discontinue oxaliplatin and continue with bevacizumab, leucovorin, and 5-FU. Treatment was continued until resectability, PD, unacceptable toxicity, or participant refusal.
Deaths Number Affected:
None
Deaths Number At Risk:
None
Serious Number Affected:
24
Serious Number At Risk:
37
Other Number Affected:
36
Other Number At Risk:
37
Study:
NCT00778102
Results Section:
NCT00778102
Adverse Events Module:
NCT00778102